Journal
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s40164-017-0091-4
Keywords
HER2; Trastuzumab; Pertuzumab; T-DM1; Bispecific antibody; Ertumaxomab; MM-111; HER2Bi-aATCs
Categories
Funding
- National Natural Science Foundation of China [81572608]
- Wuhan Science and Technology Bureau [2017060201010170]
- National High Technology Research and Development Program of China [2015AA020301]
Ask authors/readers for more resources
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The combined application of pertuzumab, trastuzumab and paclitaxel has been suggested as a standard therapy for HER2 positive advanced breast cancer. The resistance to anti-HER2 antibody has resulted in disease progression. HER2-directed bispecific antibody may be a promising therapeutic approach for these patients. Ertumaxomab enhanced the interaction of immune effector cells and tumor cells. MM-111 simultaneously binds to HER2 and HER3 and blocks downstream signaling. Besides, HER2Bi-aATC is also an alternative therapeutic approach for HER2 positive cancers. In this review, we summarized the recent advancement of HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab and T-DM1) and bispecific antibodies (MM-111, ertumaxomab and HER2Bi-aATC), especially focus on clinical trial results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available